Life Molecular Imaging (LMI) and St. Teresa's Hospital has announced that Florbetaben (18F) Injection (brand name: Neuraceq) will be available in Hong Kong from St. Teresa's Hospital by March 2025.

Neuraceq is expected to play a significant role in the early and accurate diagnosis of Alzheimer's disease (AD) and bring greater awareness of AD in Hong Kong. This marks an important step in LMI's mission to expand global access to Neuraceq®, ensuring that more patients and healthcare providers worldwide have the tools needed for early and accurate diagnosis of AD.

Neuraceq is an FDA-approved radioactive diagnostic agent for the detection of amyloid plaques in the brain of adult patients with cognitive impairment who are being evaluated for AD and other causes of cognitive decline. Neuraceq is used in clinical routine and is also a powerful diagnostic tool for the appropriate characterization of patients assessed for treatment eligibility with newly approved anti-amyloid drugs, or for enrollment in clinical trials to further support drug development in neurodegenerative diseases.

Neuraceq will facilitate the management of patients suffering from AD, including those interested in novel disease-modifying monoclonal antibody treatments recently introduced at St. Teresa's Hospital. With the availability of Neuraceq®, St. Teresa's Hospital now provides comprehensive care for AD patients from state-of-the-art diagnosis to targeted anti-amyloid therapy.

"LMI remains dedicated to expanding global access to Neuraceq®. We are pleased to partner with St. Teresa's Hospital in Hong Kong to enhance the diagnosis of patients undergoing evaluation for mild cognitive impairment (MCI) and Alzheimer's disease, while ensuring Neuraceq remains easily accessible to physicians in the region," said Ludger Dinkelborg, Ph.D., Managing Director at LMI.